MedPath

Phase 3 Study of Acupression's Bracelets in Nausea and Vomiting Induced by FEC100 Chemotherapy's Sort.

Phase 3
Completed
Conditions
Breast Neoplasms
Registration Number
NCT00268125
Lead Sponsor
Institut Claudius Regaud
Brief Summary

The purpose of this study is to demonstrate a betterment of the digestive symptomatology by the anti-emetic acupression's bracelets's use associated with hygiene and dietetic advices.

Detailed Description

Not available

Recruitment & Eligibility

Status
COMPLETED
Sex
Female
Target Recruitment
347
Inclusion Criteria
  • Woman
  • Age > 18 years
  • Well-informed written consent, signed by the patient before the beginning of the study
  • Breast cancer's diagnosis (operated or not)
  • Forecast of a treatment by FEC100 chemotherapy's sort (D1=D21) during at least 3 cycles.
  • Patient affiliated at a welfare or beneficiary from it
  • Investigator estimates that the patient is able to conform with protocol's conditions and to respect them
Exclusion Criteria
  • Operated arm's lymphedema
  • Wrist's morphology which cannot permit the bracelet's wearing (20 cm)
  • D1=D15 FEC100's treatment
  • Psychic incapability to sign a well-informed consent
  • Refusal to give a written consent
  • Patient under tutelage or guardianship
  • Pregnant or breast-feeding woman
  • Any clinical trial's participation which would impose nausea and vomiting's treatment modalities

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Primary Outcome Measures
NameTimeMethod
Reduction of 15% of stage III/IV nausea and vomiting's incidence.
Secondary Outcome Measures
NameTimeMethod

Trial Locations

Locations (3)

Centre Oscar Lambret

🇫🇷

Lille, France

Centre Paul STRAUSS

🇫🇷

Strasbourg, France

Institut Claudius Regaud

🇫🇷

Toulouse, France

Centre Oscar Lambret
🇫🇷Lille, France

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.